SCDT-44. CLINICAL EVALUATION OF REGADENOSON AS A PHARMACOLOGIC AGENT TO TRANSIENTLY MODIFY BLOOD-BRAIN BARRIER INTEGRITY TO FACILITATE ENTRY OF CHEMOTHERAPY INTO BRAIN PARENCHYMA

Previous pre-clinical and rodent studies have demonstrated that adenosine A2A receptor activation can transiently modify: 1) blood-brain barrier (BBB) integrity thereby increasing entry of high molecular weight dextran and temozolomide to the central nervous system, 2) the actions of p-glycoprotein...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Grossman, Stuart, Rudek, Michelle, Jackson, Sadhana, Bynoe, Margaret
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691893/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.1124
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars